These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 10965287)
1. Reducing relapse in depressed outpatients with atypical features: a pilot study. Jarrett RB; Kraft D; Schaffer M; Witt-Browder A; Risser R; Atkins DH; Doyle J Psychother Psychosom; 2000; 69(5):232-9. PubMed ID: 10965287 [TBL] [Abstract][Full Text] [Related]
2. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298 [TBL] [Abstract][Full Text] [Related]
3. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Stewart JW; McGrath PJ; Quitkin FM Am J Psychiatry; 1992 May; 149(5):615-9. PubMed ID: 1575250 [TBL] [Abstract][Full Text] [Related]
4. Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care. Jarrett RB; Minhajuddin A; Vittengl JR; Clark LA; Thase ME J Consult Clin Psychol; 2016 Apr; 84(4):365-76. PubMed ID: 26654211 [TBL] [Abstract][Full Text] [Related]
5. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Hollon SD; DeRubeis RJ; Shelton RC; Amsterdam JD; Salomon RM; O'Reardon JP; Lovett ML; Young PR; Haman KL; Freeman BB; Gallop R Arch Gen Psychiatry; 2005 Apr; 62(4):417-22. PubMed ID: 15809409 [TBL] [Abstract][Full Text] [Related]
7. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder. Vittengl JR; Anna Clark L; Thase ME; Jarrett RB Psychiatry Res; 2017 Jul; 253():174-181. PubMed ID: 28388454 [TBL] [Abstract][Full Text] [Related]
8. How much cognitive therapy, for which patients, will prevent depressive relapse? Jarrett RB; Vittengl JR; Clark LA J Affect Disord; 2008 Dec; 111(2-3):185-92. PubMed ID: 18358541 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder. Vittengl JR; Clark LA; Thase ME; Jarrett RB J Affect Disord; 2016 Jul; 199():148-56. PubMed ID: 27104803 [TBL] [Abstract][Full Text] [Related]
10. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Segal ZV; Kennedy S; Gemar M; Hood K; Pedersen R; Buis T Arch Gen Psychiatry; 2006 Jul; 63(7):749-55. PubMed ID: 16818864 [TBL] [Abstract][Full Text] [Related]
11. Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder. Vittengl JR; Clark LA; Thase ME; Jarrett RB J Consult Clin Psychol; 2014 Dec; 82(6):1049-59. PubMed ID: 25045908 [TBL] [Abstract][Full Text] [Related]
12. Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder. Vittengl JR; Clark LA; Thase ME; Jarrett RB Psychotherapy (Chic); 2015 Jun; 52(2):268-77. PubMed ID: 25985046 [TBL] [Abstract][Full Text] [Related]
13. Treatment of atypical depression with cognitive therapy or phenelzine. Levitan RD Arch Gen Psychiatry; 2000 Nov; 57(11):1084; author reply 1084-5. PubMed ID: 11074875 [No Abstract] [Full Text] [Related]
14. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial. Nordenskjöld A; von Knorring L; Ljung T; Carlborg A; Brus O; Engström I J ECT; 2013 Jun; 29(2):86-92. PubMed ID: 23303421 [TBL] [Abstract][Full Text] [Related]
15. Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression. Vittengl JR; Clark LA; Jarrett RB J Affect Disord; 2009 Jan; 112(1-3):135-43. PubMed ID: 18539337 [TBL] [Abstract][Full Text] [Related]
16. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. Jarrett RB; Minhajuddin A; Gershenfeld H; Friedman ES; Thase ME JAMA Psychiatry; 2013 Nov; 70(11):1152-60. PubMed ID: 24005123 [TBL] [Abstract][Full Text] [Related]
17. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Rush AJ; Trivedi MH; Wisniewski SR; Nierenberg AA; Stewart JW; Warden D; Niederehe G; Thase ME; Lavori PW; Lebowitz BD; McGrath PJ; Rosenbaum JF; Sackeim HA; Kupfer DJ; Luther J; Fava M Am J Psychiatry; 2006 Nov; 163(11):1905-17. PubMed ID: 17074942 [TBL] [Abstract][Full Text] [Related]
18. A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression. Mercier MA; Stewart JW; Quitkin FM J Clin Psychiatry; 1992 May; 53(5):166-70. PubMed ID: 1592844 [TBL] [Abstract][Full Text] [Related]
19. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Kellner CH; Knapp RG; Petrides G; Rummans TA; Husain MM; Rasmussen K; Mueller M; Bernstein HJ; O'Connor K; Smith G; Biggs M; Bailine SH; Malur C; Yim E; McClintock S; Sampson S; Fink M Arch Gen Psychiatry; 2006 Dec; 63(12):1337-44. PubMed ID: 17146008 [TBL] [Abstract][Full Text] [Related]
20. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]